2020 BIO Investor Forum Buzz of BIO Finalist
Curevo Vaccine is a US-based clinical stage biotech company dedicated to developing next generation vaccines that bring effectiveness, safety, tolerability, and advanced production capabilities to the market - quickly and efficiently.
Curevo's lead product, a sub-unit Zoster (Shingles) Vaccine has completed Phase I (90 subject trial). Results are showing a promising safety profile and the desired immune responses. CRV-101 is inducing a robust vaccine specific and dose dependent antibody immune response. Anti-gE antibody geometric mean concentrations remain well above pre-vaccination levels at 1 year across all dosing cohorts.
We are targeting a unique position in the $4B+ Varicella Zoster Virus vaccine market today, growing to $21B by 20301.
On the strength of our clinical data and pre-clinical pipeline and unmet market opportunity worldwide, we are looking for partners and investors to support the next stage of clinical development.
Curevo Vaccine is a US-based clinical stage biotech company dedicated to developing next generation vaccines that bring effectiveness, safety, tolerability, and advanced production capabilities to the market - quickly and efficiently.
Curevo's lead product, a sub-unit Zoster (Shingles) Vaccine has completed Phase I (90 subject trial). Results are showing a promising safety profile and the desired immune responses. CRV-101 is inducing a robust vaccine specific and dose dependent antibody immune response. Anti-gE antibody geometric mean concentrations remain well above pre-vaccination levels at 1 year across all dosing cohorts.
We are targeting a unique position in the $4B+ Varicella Zoster Virus vaccine market today, growing to $21B by 20301.
On the strength of our clinical data and pre-clinical pipeline and unmet market opportunity worldwide, we are looking for partners and investors to support the next stage of clinical development.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Washington
Company HQ Country:
United States
Year Founded:
2018
Main Therapeutic Focus:
Infectious Diseases
Lead Product in Development:
CRV-101 for the prevention of Zoster (Shingles)
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
